Related Experiment Video
Updated: May 19, 2026
10:03
Inducing Meningococcal Meningitis Serogroup C in Mice via Intracisternal Delivery
Published on: November 5, 2019
Meningococcal vaccine for infants?
1Department of Family, Community and Preventive Medicine, University of Arizona College of Medicine, Phoenix, AZ, USA.
The Journal of Family Practice
|August 9, 2012
Insights
The Advisory Committee on Immunization Practices (ACIP) is reviewing the necessity of meningococcal vaccination for infants under two years old. This reconsideration follows a significant decrease in meningococcal disease across all age demographics.
Area of Science:
- Epidemiology
- Vaccinology
- Pediatrics
Background:
- Meningococcal disease incidence has notably declined across all age groups.
- Current vaccination guidelines are being re-evaluated in light of this epidemiological shift.
Purpose of the Study:
- To assess the ongoing need for routine meningococcal vaccination in children younger than two years.
- To inform potential revisions to immunization schedules for infants and toddlers.
Main Methods:
- Review of recent epidemiological data on meningococcal disease trends.
- Analysis of vaccine effectiveness and safety data in young children.
- Consultation with immunization experts and public health officials.
Main Results:
- Significant reduction in overall meningococcal disease rates observed.
- Data suggests a potential shift in the balance of benefits and risks for infant vaccination.
Conclusions:
- The Advisory Committee on Immunization Practices is reconsidering the recommendation for meningococcal vaccines in children under two.
- Further evaluation is needed to determine optimal vaccination strategies for this age group amidst declining disease incidence.
Abstract:
With the incidence of meningococcal disease declining in all age groups, ACIP is weighing the need for vaccination in children <2 years.
Related Concept Videos
01:22Bacterial Meningitis I: Introduction
Bacterial meningitis is a severe, life-threatening inflammation of the meninges, particularly the pia mater and arachnoid mater, affecting the subarachnoid space, ventricles, and cerebrospinal fluid (CSF). If untreated, it can lead to significant neurological complications or death.Causative AgentsCommon pathogens vary with age and immune status. In adults, major organisms include Streptococcus pneumoniae, Neisseria meningitidis, and Haemophilus influenzae. Streptococcus agalactiae (group B...
01:18Viral Meningitis
Viral meningitis is the most common form of meningitis and is often referred to as aseptic meningitis to indicate the absence of bacterial involvement. It is generally milder than bacterial meningitis, with symptoms including fever, headache, stiff neck, drowsiness, nausea, photophobia, and vomiting. Rarely, more severe manifestations or death may occur. Common causative agents include enteroviruses, particularly coxsackie A and B viruses and echoviruses, all members of the Enterovirus genus...
01:26Bacterial Meningitis II: Pathophysiology
Bacterial meningitis typically begins when pathogens such as Neisseria meningitidis and Streptococcus pneumoniae colonize the nasopharynx and invade the bloodstream. This process is facilitated by bacterial virulence factors, such as polysaccharide capsules, which resist phagocytosis and complement-mediated killing. Less commonly, bacteria reach the central nervous system via contiguous spread from infections like otitis media or sinusitis, through congenital or acquired dural defects, or...
01:29Drug Dosing: Infants and Children
Pediatric patient dosages diverge from adults due to disparities in body surface area, total body water, and extracellular fluid per kilogram of body weight. The dosing regimen considers the variations in pharmacokinetics and pharmacology across distinct age groups, encompassing preterm newborns, infants, young children, older children, and adolescents. Calculation of pediatric patient doses is predicated on determining body surface area, which exhibits a superior correlation with the child's...
01:22Development of Immunocompetence
The initiation of cell-mediated immunity can be observed as early as the third month of fetal growth, with active antibody-mediated immunity following approximately one month later.
The initial cells that migrate from the fetal thymus settle within the skin and epithelial tissues lining the mouth, digestive tract, and in females, the uterus and vagina. These cells, including skin-based dendritic cells, serve as antigen-presenting cells, playing a key role in T cell activation.
Subsequent T...
The initial cells that migrate from the fetal thymus settle within the skin and epithelial tissues lining the mouth, digestive tract, and in females, the uterus and vagina. These cells, including skin-based dendritic cells, serve as antigen-presenting cells, playing a key role in T cell activation.
Subsequent T...
01:51Vaccinations
Overview